The SIRveNIB Study

SIRveNIB is a multi-centre prospective randomised open-label study to compare the efficacy and safety of SIR-Spheres® Y-90 resin microspheres versus sorafenib. The study recruited >360 patients in Asia who were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation.

The primary endpoint of the SIRveNIB study is Overall Survival. Secondary endpoints include Safety, Progression-Free Survival (PFS) in the liver, PFS at any site, Tumour Response Rate, Liver Resection Rate, Liver Transplantation Rate, Quality of Life, and Healthcare Costs.

The study completed enrolment in May 2016 and results are expected by mid-2017.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage